The SGLT2 inhibitor group showed a significantly higher rate of sleep quality improvement (65.2%, p < 0.001), accompanied by reductions in anxiety (BAI) and improvements across multiple SF‐36 domains. Here, SLC5A2 is linked to Anxiety.